CA2416538A1 - Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese - Google Patents

Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese Download PDF

Info

Publication number
CA2416538A1
CA2416538A1 CA002416538A CA2416538A CA2416538A1 CA 2416538 A1 CA2416538 A1 CA 2416538A1 CA 002416538 A CA002416538 A CA 002416538A CA 2416538 A CA2416538 A CA 2416538A CA 2416538 A1 CA2416538 A1 CA 2416538A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002416538A
Other languages
English (en)
Inventor
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Kenneth J. Hillan
Scot A. Marsters
James Pan
Nicholas F. Paoni
Jean-Philippe F. Stephan
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Weilan Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/fr
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/fr
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,280 external-priority patent/US7115398B2/en
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/fr
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/fr
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/fr
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2416538A1 publication Critical patent/CA2416538A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

La présente invention concerne des compositions et des méthodes permettant de stimuler ou d'inhiber l'angiogenèse et/ou la vascularisation cardiaque chez les mammifères, notamment les humains. Ces compositions pharmaceutiques renferment des polypeptides ou leurs antagonistes ayant été identifiés pour un ou plusieurs de ces usages. Parmi les troubles pouvant être diagnostiqués, prévenus, ou traités avec ces compositions, on note les traumas tels que les blessures, divers cancers, et les troubles vasculaires, notamment l'athérosclérose et l'hypertrophie cardiaque. Par ailleurs, l'invention concerne de nouveaux polypeptides et des molécules d'acides nucléiques codant ces polypeptides. Cette invention concerne également des vecteurs et des cellules hôtes contenant ces séquences d'acides nucléiques, des molécules de polypeptides chimères contenant les polypeptides de l'invention fusionnés aux séquences de polypeptides hétérologues, des anticorps qui se lient à ces polypeptides, ainsi que des méthodes de production desdits polypeptides.
CA002416538A 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese Abandoned CA2416538A1 (fr)

Applications Claiming Priority (73)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US60/219,556 2000-07-20
US22066400P 2000-07-25 2000-07-25
US22062400P 2000-07-25 2000-07-25
US60/220,624 2000-07-25
US60/220,664 2000-07-25
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
USPCT/US00/20710 2000-07-28
US22269500P 2000-08-02 2000-08-02
US60/222,695 2000-08-02
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
US09/643,657 2000-08-17
USPCT/US00/23522 2000-08-23
PCT/US2000/023522 WO2001016319A2 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US23097800P 2000-09-07 2000-09-07
US60/230,978 2000-09-07
US60/000,000 2000-09-15
US66461000A 2000-09-18 2000-09-18
US66535000A 2000-09-18 2000-09-18
US09/665,350 2000-09-18
US09/664,610 2000-09-18
US24292200P 2000-10-24 2000-10-24
US60/242,922 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
US09/709,238 2000-11-08
USPCT/US00/30952 2000-11-08
USPCT/US00/30873 2000-11-10
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique
USPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
US09/747,259 2000-12-20
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
USPCT/US00/34956 2000-12-20
US09/767,609 2001-01-22
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US79649801A 2001-02-28 2001-02-28
USPCT/US01/06520 2001-02-28
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US09/796,498 2001-02-28
PCT/US2001/006666 WO2001066740A2 (fr) 2000-03-03 2001-03-01 Compositions et methodes de traitement de maladies d'origine immune
USPCT/US01/06666 2001-03-01
US80270601A 2001-03-09 2001-03-09
US09/802,706 2001-03-09
US80868901A 2001-03-14 2001-03-14
US09/808,689 2001-03-14
US09/816,744 2001-03-22
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/828,366 2001-04-05
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/854,280 2001-05-10
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/854,208 2001-05-10
US09/866,034 2001-05-25
USPCT/US01/17092 2001-05-25
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/017092 WO2001092331A2 (fr) 2000-05-30 2001-05-25 Compositions et methodes de traitement de maladies d'origine immune
US09/866,028 2001-05-25
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
USPCT/US01/17443 2001-05-30
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US09/870,574 2001-05-30
PCT/US2001/017443 WO2002016611A2 (fr) 2000-08-24 2001-05-30 Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
USPCT/US01/17800 2001-06-01
PCT/US2001/017800 WO2001093983A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
USPCT/US01/19692 2001-06-20
PCT/US2001/019692 WO2002000690A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
USPCT/US01/00000 2001-06-28
PCT/US2001/021735 WO2002008284A2 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese

Publications (1)

Publication Number Publication Date
CA2416538A1 true CA2416538A1 (fr) 2002-01-31

Family

ID=56290165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002416538A Abandoned CA2416538A1 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese

Country Status (5)

Country Link
EP (1) EP1309685A2 (fr)
JP (5) JP2004516013A (fr)
AU (1) AU2001271973A1 (fr)
CA (1) CA2416538A1 (fr)
WO (1) WO2002008284A2 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012179A2 (fr) 1997-09-12 2000-06-28 Apotech R&D S.A. Recepteurs "trail" riches en cysteine
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1623993A3 (fr) * 1999-09-01 2006-06-07 Genetech, Inc. Protéines sécrétées et transmembranaire et acides nucléiques les codant
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP1881004B1 (fr) * 2000-04-21 2012-07-25 Fuso Pharmaceutical Industries, Ltd. Nouvelle collectine
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2648046A1 (fr) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
EP2275549A1 (fr) * 2000-06-23 2011-01-19 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
JP2004506413A (ja) * 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
US7164009B2 (en) 2000-09-15 2007-01-16 Genentech, Inc. Pro9821 polypeptides
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US20060141453A9 (en) 2000-11-03 2006-06-29 Qun-Yong Zhou Prokineticin polypeptides, related compositions and methods
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1530590A2 (fr) * 2002-03-22 2005-05-18 Bioxell S.p.a. Nouveau recepteur trem (recepteur declencheur exprime sur les cellules myeloides) et utilisations correspondantes
CA2480419A1 (fr) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Facteur de croissance associe a une antiopoietine
EP2011886A3 (fr) * 2002-04-16 2009-02-11 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
WO2004022087A1 (fr) * 2002-09-04 2004-03-18 Takeda Pharmaceutical Company Limited Utilisation d'un gene associe a une maladie
EP1562587A4 (fr) * 2002-09-11 2006-07-19 Genentech Inc Compositions et methodes pour le traitement de maladies du systeme immunitaire
WO2004028479A2 (fr) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
MXPA05009743A (es) 2003-03-12 2006-03-09 Genentech Inc Composiciones con actividad hematopoyetica e inmune.
KR100945327B1 (ko) 2003-07-08 2010-03-08 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
AU2005249377A1 (en) 2004-04-14 2005-12-15 Genentech, Inc. Compositions and methods comprising an EGFL7 antagonist for modulating vascular development
ES2405273T3 (es) 2004-06-24 2013-05-30 Mayo Foundation For Medical Education And Research Polipéptido coestimulador B7-H5
RU2007104022A (ru) 2004-07-02 2008-08-10 Дженентек, Инк. (Us) Композиции для лечения неходжкинской лимфомы и способы их применения
EP1789070B1 (fr) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Influence du taj sur les fonctions neuronales
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
AR063760A1 (es) 2006-11-02 2009-02-18 Genentech Inc Anticuerpos anti-factor d humanizados y usos de los mismos
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP5583591B2 (ja) 2007-11-21 2014-09-03 アムジエン・インコーポレーテツド Ｗｉｓｅ結合抗体及びエピトープ
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
PL2280996T3 (pl) 2008-05-06 2017-07-31 Genentech Inc WARIANTY CRIg O DOJRZAŁYM POWINOWACTWIE
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
EP2427203B1 (fr) 2009-05-05 2018-10-17 Novimmune S.A. Anticorps anti-il-17f et leurs utilisation
PE20120902A1 (es) 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados
AT508569A1 (de) * 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
LT2499161T (lt) 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
EP3597666A3 (fr) 2011-07-01 2020-04-22 NGM Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles métaboliques et de maladies
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9925242B2 (en) 2012-12-27 2018-03-27 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
EP2945642B1 (fr) * 2013-01-17 2024-02-21 Medizinische Hochschule Hannover Protéine du facteur 1 destiné à être utilisés dans le traitement ou la prévention de maladies
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
JP6463359B2 (ja) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド 補体関連病態を治療するための組成物及び方法
RU2707531C2 (ru) 2013-10-28 2019-11-27 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Модели рака и соответствующие способы
EP3738981A1 (fr) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
CN106536561A (zh) 2014-05-01 2017-03-22 豪夫迈·罗氏有限公司 抗‑因子d抗体变体及其用途
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3888672A1 (fr) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Méthodes de traitement de troubles associés aux acides biliaires
CA3034399A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19
GB201906052D0 (en) * 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
JP7064179B2 (ja) 2020-11-30 2022-05-10 富士電機株式会社 水分吸着材

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032221A2 (fr) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
WO2000053751A1 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Procedes et compositions pour l'inhibition de la croissance de cellules neoplasiques
EP1017707A4 (fr) * 1997-08-29 2004-04-28 Human Genome Sciences Inc 29 proteines humaines secretees
WO1999043802A2 (fr) * 1998-02-27 1999-09-02 Sagami Chemical Research Center Proteines humaines possedant des domaines transmembranaires et adn codant ces proteines
DK1490386T3 (da) * 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
EP1068307A1 (fr) * 1998-03-31 2001-01-17 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
MXPA01002546A (es) * 1998-09-14 2004-06-11 Genentech Inc Promocion o inibhicion de angiogenesis y cardiovascularizacion.
KR20030002292A (ko) * 1999-03-08 2003-01-08 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
JP2004506413A (ja) * 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法

Also Published As

Publication number Publication date
JP2009039119A (ja) 2009-02-26
WO2002008284A3 (fr) 2003-03-13
JP2012005493A (ja) 2012-01-12
WO2002008284A2 (fr) 2002-01-31
JP2009039118A (ja) 2009-02-26
JP2004516013A (ja) 2004-06-03
JP2009039117A (ja) 2009-02-26
AU2001271973A1 (en) 2002-02-05
JP6033531B2 (ja) 2016-11-30
EP1309685A2 (fr) 2003-05-14

Similar Documents

Publication Publication Date Title
US7135334B2 (en) PRO20044 nucleic acids
JP6033531B2 (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
US7265210B2 (en) Anti-PRO9821 antibodies
US20040043927A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2412211A1 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
US20060074033A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070191270A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060073552A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030224984A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060073558A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7332578B2 (en) Anti-pro4407 antibodies
EP2042597A1 (fr) Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
US7238790B2 (en) PRO1313 polypeptides
US20060073556A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060074228A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2075253A1 (fr) Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
JP2015037408A (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
EP1944317A2 (fr) Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued